Margetuximab: An active alternative for later‐line therapy in ...

The SOPHIA phase 3 trial showed margetuximab plus chemotherapy improved progression-free survival (PFS) but not overall survival (OS) compared to trastuzumab plus chemotherapy in HER2-positive advanced breast cancer patients. Margetuximab's Fc engineering enhances antibody-dependent cell-mediated cytotoxicity (ADCC), offering a potential treatment alternative despite no OS benefit.